clinical development programs. The net profit over the reported period
amounts to EUR 18.0 million against a loss of EUR16.0 million over the
full year 2007.
- The Company expects to see an increase in its operating
expenses in the second half of the year as it starts to invest in the
Phase III program for microplasmin in back of the eye disease
- As of June 30, 2008, ThromboGenics had EUR 40.4 million in
cash and cash equivalents. This compares to EUR49.3 million on June 30,
2007 and EUR 46.1 million on December 31, 2007. This cash position does
not yet include the upfront payment from Roche of EUR 30 million that
was only received in July 2008.
Prof. Desire Collen, CEO and Chairman of ThromboGenics, commenting on today's announcement, said: "ThromboGenics has made excellent progress in the first half of 2008. We have not only seen very promising clinical data with our lead product, microplasmin, but also signed a significant co-development deal with Roche for our unique anti-cancer agent, TB-403. The ability of microplasmin to resolve certain back of the eye conditions coupled with the financial benefits which our alliance with Roche brings, means we are now well-positioned to advance microplasmin into its Phase III clinical development program. As ThromboGenics continues to transform itself into a late-stage development company, I am confident that we have all the tools available to ensure our corporate success."
For the full report of these results please go to http://www.thrombogenics.com
ThromboGenics is a biotechnology company focused on discovery and
development of biopharmaceuticals for the treatment of eye disease,
vascular disease and cancer. The Company has several programs in Phase II
clinical development including microp
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved